

**OTU7B Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP14281b****Specification**

---

**OTU7B Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q6GQO9](#)**OTU7B Antibody (C-term) Blocking Peptide - Additional Information**

Gene ID 56957

**Other Names**

OTU domain-containing protein 7B, Cellular zinc finger anti-NF-kappa-B protein, Zinc finger A20 domain-containing protein 1, Zinc finger protein Cezanne, OTUD7B, ZA20D1

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**OTU7B Antibody (C-term) Blocking Peptide - Protein Information**

Name OTUD7B

Synonyms ZA20D1

**Function**

Negative regulator of the non-canonical NF-kappa-B pathway that acts by mediating deubiquitination of TRAF3, an inhibitor of the NF-kappa-B pathway, thereby acting as a negative regulator of B-cell responses. In response to non-canonical NF-kappa-B stimuli, deubiquitinates 'Lys-48'-linked polyubiquitin chains of TRAF3, preventing TRAF3 proteolysis and over-activation of non-canonical NF- kappa-B. Negatively regulates mucosal immunity against infections (By similarity). Deubiquitinates ZAP70, and thereby regulates T cell receptor (TCR) signaling that leads to the activation of NF-kappa-B (PubMed:<a href="http://www.uniprot.org/citations/26903241" target="\_blank">26903241</a>). Plays a role in T cell homeostasis and is required for normal T cell responses, including production of IFNG and IL2 (By similarity). Mediates deubiquitination of EGFR (PubMed:<a href="http://www.uniprot.org/citations/22179831" target="\_blank">22179831</a>). Has deubiquitinating activity toward 'Lys-11', 'Lys-48' and 'Lys-63'-linked polyubiquitin chains (PubMed:<a href="http://www.uniprot.org/citations/27732584" target="\_blank">27732584</a>). Has a much higher catalytic rate with 'Lys-11'-linked polyubiquitin chains (in vitro); however the physiological significance of these data are unsure (PubMed:<a href="http://www.uniprot.org/citations/27732584" target="\_blank">27732584</a>).

Hydrolyzes both linear and branched forms of polyubiquitin.

**Cellular Location**

Cytoplasm. Nucleus Note=Shuttles between cytoplasm and the nucleus in a XPO1/CRM1-dependent manner.

**Tissue Location**

Widely expressed. Abundant in kidney, heart and fetal liver. Expressed differentially among B-cells at distinct developmental stages. Higher expression seen in primary immature B- cells as compared to the mature cells.

**OTU7B Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**OTU7B Antibody (C-term) Blocking Peptide - Images****OTU7B Antibody (C-term) Blocking Peptide - Background**

OTU7B has deubiquitinating activity that is directed towards 'Lys-48' or 'Lys-63'-linked polyubiquitin chains. Hydrolyzes both linear and branched forms of polyubiquitin. Negative regulator of nuclear factor NF-kappa-B.

**OTU7B Antibody (C-term) Blocking Peptide - References**

Bremm, A., et al. Nat. Struct. Mol. Biol. 17(8):939-947(2010) Jin, Z., et al. Cell 137(4):721-735(2009) Enesa, K., et al. J. Biol. Chem. 283(27):18582-18590(2008) Bohgaki, M., et al. Biochim. Biophys. Acta 1783(5):826-837(2008) Enesa, K., et al. J. Biol. Chem. 283(11):7036-7045(2008)